10th Sep 2013 14:01
For immediate release | 10 September 2013 |
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR dealing: Abcam plc Annual Bonus Plan - Deferred Share Award
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools announces that on 10 September 2013 following the publication of the audited results for the year ended 30 June 2013, the following Deferred Share Awards in the form of Nil Cost Options (the "Award") have been granted to the Executive Directors and PDMRs under the Abcam plc Annual Bonus Plan:
Name | Number of 0.2 pence Ordinary Shares subject to the Award
| |
Executive Directors: | Jonathan Milner | 17,278 |
Jim Warwick | 12,931 | |
Jeff Iliffe | 12,262 | |
PDMRs: | Mark Bushfield | 6,291 |
Jane Cooke | 3,899 | |
Philippe Cotrel | 6,291 | |
Danielle Miller | 1,378 | |
Ed Ralph | 5,230 |
The Nil Cost Options subject to the Awards will be released to the Executive Directors and PDMRs on the second anniversary of grant subject to continued employment with the Company.
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Andy Crossley - Corporate Broking
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 125,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.
Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices and ships to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com
Related Shares:
ABC.L